According to a report made available on Wednesday by Briefing.com, Canaccord Genuity Group initiated coverage of Olink Holding AB (publ) (NASDAQ: OLK) shares in a research report released on Wednesday. The organization recommended “buying” the stock and established a price objective of $28.00. In addition, Canaccord Genuity Group has a price target for the stock that indicates there is room for it to move higher than its current price of 20.95%. This is indicated by the fact that the price target has been set.
Recently published reports on the company have come from several other equity research analysts. These studies emphasize more recent happenings. Olink Holding AB was the subject of a research report that Canaccord Genuity Group issued Wednesday as part of their company coverage (publ). They suggested a “buy” investment in the company and determined that the price target would be $28.00. In a report made public on November 15th, the research firm SVB Leerink gave the company an “outperform” rating and increased their price objective on Olink Holding AB (publ) from $25.00 to $27.00. The report was titled “Olink Holding AB (publ) Price Objective Increased.” In a research note that was published on Friday, November 11th, Morgan Stanley upgraded Olink Holding AB (publ) from “equal weight” to “buy” and raised their target price on the stock from $16.00 to $17.00. They also raised their target price for the stock from $16.00 to $17.00. There are a total of three market analysts who have given the stock a recommendation to buy, while there are a total of two who have given the stock a rating of hold. According to Bloomberg, the current consensus rating for the company is “Moderate Buy,” and the associated price objective for the company is a consensus of $25.50.
On Wednesday morning, the opening price of an OLK share was $23.17 before the market opened. The price of the company has a moving average of $19.46 over the past fifty days, and over the past 200 days, that number has decreased from $16.07.46 over the past fifty days, and over the past 200 days, that number has decreased to $16.07. During the last 52 weeks, the price of Olink Holding AB has fluctuated between $8.39 and $24.93 on average, with a median price of $24.93. A price-to-earnings ratio of -105.32 and a beta value of 1.36 are both associated with the stock. The company’s total value, as measured by its market capitalization, is $2.76 billion.
In the most recent few months, several institutional investors and hedge funds have altered the proportion of OLK in their portfolios by either increasing or decreasing the amount of the asset. During the third quarter of this fiscal year, UBS Group AG acquired a 55.9% larger share of Olink Holding AB (publ), increasing its stake in the company by that amount. UBS Group AG now holds a total of 5,700 shares following the acquisition of an additional 2,043 shares during the most recent quarter. The value of UBS Group AG’s stock in the company as of right now is $69,000. Tower Research Capital LLC (TRC) made a new investment in Olink Holding AB during the third quarter by shelling out approximately $140,000 in cash for the purchase (publ). Olink Holding AB received an investment from Raymond James & Associates in the amount of approximately 209,000 dollars during the first quarter (publ). Cubist Systematic Strategies LLC spent approximately $227,000 during the third quarter to acquire a new stake in Olink Holding AB. This was accomplished by investing in the company (PUB). In the second quarter, State Street Corporation shelled out approximately $229,000 to purchase a new stake in Olink Holding AB. This purchase was the crowning achievement for the company (publ). At this point, institutions own 30.93% of the company’s stock.
Because Olink Holding AB provides a wide selection of goods and services, it is possible for institutions engaged in research in the field of life sciences to choose those tailored to meet their requirements most effectively. These organizations can work in academia, government, biotechnology, and pharmaceuticals (publ). Its products include Olink Target for conditions related to cancer, neurological disease, or inflammation; Olink Focus for customers who have identified multiple proteins of interest or a protein signature to focus on; and Olink Explore for customers who have conditions related to cardiovascular and metabolic disease, oncology, neurological disease, or inflammation.